3 years ago

Focal regression of a primary melanoma, fading lentigines, and poliosis in metastatic melanoma treated with anti-PD-1

R. Sturm, D. Lambie, S. Thomas, V. Atkinson, H. Schaider, H.P. Soyer, A. Laino, K. Nufer, L. Adams, B. Shepherd
Pembrolizumab®, a first line immune checkpoint inhibitor, has shown good clinical activity with an acceptable safety profile, in the management of metastatic melanoma.1, 2 We report a patient with metastatic melanoma, treated with anti-PD-1, who demonstrated metastatic disease regression, focal complete regression of a primary melanoma, partial regression of several solar lentigines, and a patch of poliosis superficial to a thigh metastatic deposit. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/jdv.14678

You might also like
Never Miss Important Research

Researcher is an app designed by academics, for academics. Create a personalised feed in two minutes.
Choose from over 15,000 academics journals covering ten research areas then let Researcher deliver you papers tailored to your interests each day.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.